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motility generally should be reserved for preterm infants who exhibit signs of emesis or regurgitation of feedings, regardless of whether apnea is present.
Xanthine Therapy
Methylxanthines have been the mainstay of pharmacologic treatment of apnea; there is now a 25-year history of their use in infants. Both theophylline and caffeine are used and have multiple physiologic and pharmacologic mechanisms of action. Xanthine therapy increases minute ventilation, improves CO 2 sensitivity, decreases hypoxic depression of breathing, enhances diaphragmatic activity, and decreases periodic breathing. The precise pharmacologic basis for these actions, which are mediated by an increase in respiratory neural output, is still under investigation. A likely major mechanism of action is through competitive antagonism of adenosine receptors. Adenosine acts as an inhibitory neuroregulator in the central nervous system and is released during hypoxia. Neonates exhibit hypoxic respiratory depression, and the ability of methylxanthines to block this response may contribute to their effect on apnea. Other adenosinemediated pathways of respiratory neural inhibition also may be blocked by xanthine therapy. Our understanding of the role of xanthines may be enhanced by future studies correlating physiologic observations with labeling and localization of both adenosine and its receptor subtypes in respiratory-related regions of the developing brainstem.
Treatment usually is initiated with a loading dose followed by maintenance therapy. Theophylline is available in oral and intravenous preparations. The intravenous form is aminophylline, a complex of theophylline and ethylenediamine. For oral theophylline, the loading dose is 5 to 6 mg/kg, followed by 1 to 2 mg/kg every 8 to 12 hours. Dosing of intravenous aminophylline is increased by 20% because it is 85% theophylline by weight. Caffeine is similarly available for both oral and intravenous use and has some advantages over theophylline. Because it has a higher therapeutic index, toxicity is less of a concern. Also, once-daily dosing is possible due to its longer half-life. A typical loading dose of 20 mg/kg caffeine citrate is followed in 24 hours by 5 to 8 mg/kg per dose, administered once every 24 hours. A recent Cochrane review of the use of methylxanthines concluded that both theophylline and caffeine are effective in reducing both apnea episodes and the use of mechanical ventilation in preterm infants. In many centers (including ours), xanthine therapy is employed routinely to enhance successful extubation of very low-birthweight infants. The review further concluded that caffeine was the preferable drug and that studies of the long-term effects of methylxanthine treatment on growth and development were needed. These issues are being addressed in an ongoing international trial in which preterm infants are being randomized to caffeine or placebo therapy, with neurodevelopmental outcome as a major endpoint.
Elimination of methylxanthines is prolonged in infants compared with children or adults, and it is especially prolonged in preterm infants. The half-life of caffeine in preterm infants averages 50 hours. The metabolic pathways for the elimination of theophylline are underdeveloped in the preterm infant and include conversion by methylation to caffeine. Overall, disposition can be highly unpredictable. Serum concentrations of methylxanthines may vary considerably among infants and are not entirely predictable based on dosage. Serum concentrations of theophylline should be monitored whenever aminophylline or theophylline is used. Caffeine levels are less critical, but they also may be followed at the beginning of treatment. Xanthine therapy should be discontinued at least 1 to 2 weeks prior to discharge, a guideline that is is especially relevant for caffeine because of its longer half-life.
The methylxanthines have some well-documented adverse effects. Toxic levels may produce tachycardia, cardiac dysrhythmias, feeding intolerance, and infrequently seizures, although these effects are seen less commonly with caffeine at the usual therapeutic doses. Mild diuresis is caused by all methylxanthines. Certain drug-drug interactions are relevant to methylxanthines, particularly medications that affect liver function and those whose clearance depends on cytochrome P-450. The half-life of methylxanthines is prolonged in infants who have liver disease. The observation that xanthine therapy causes an increase in metabolic rate and oxygen consumption of approximately 20% suggests that caloric demands may be increased with this therapy at a time when nutritional intake already is compromised.
Role of Continuous Positive Airway Pressure
Nonpharmacologic strategies also are used widely in the treatment of apnea. Tactile stimulation often terminates a brief episode, and this is a frequent nursing intervention in neonatal intensive care units. Continuous positive airway pressure (CPAP) at 5 to 6 cm H 2 O is relatively safe and effective therapy. Because longer episodes of apnea frequently involve an obstructive component, CPAP appears to be effective by splinting the upper airway with positive pressure and decreasing the risk of pharyngeal or laryngeal obstruction. CPAP also probably benefits apnea by increasing functional residual capacity (FRC), thereby improving oxygenation status. It has been shown that at higher FRC, time from cessation of breathing to desaturation and resultant bradycardia is prolonged. High-flow nasal cannula therapy recently was suggested as an equivalent treatment modality that may allow CPAP delivery while enhancing mobility of the infant. For severe or refractory episodes, endotracheal intubation and artificial ventilation may be needed. Minimal ventilator settings should be used to allow for spontaneous ventilatory efforts and to minimize the risk of barotrauma.
Management of Persistent Apnea and Role of Home Monitoring
Apnea of prematurity generally resolves by about 36 to 40 weeks' postconceptional age. However, in the most immature infants (24 to 28 weeks' gestation), apnea frequently persists beyond 36 weeks' postpostconceptional age and may persist beyond 40 weeks' postpostconceptional age. Recent findings suggest that cardiorespiratory events in such infants return to the baseline "normal" level at about 43 to 44 weeks' postconceptional age. In other words, beyond 43 to 44 weeks' postconceptional age, the incidence of cardiorespiratory events in preterm infants does not significantly exceed that in term babies (Fig. 2) .
Apnea and bradycardia are resolved in many preterm infants by the time they are ready for hospital discharge, as determined by maturation of temperature control and feeding pattern. An apnea-free observation period, usually ranging from 3 to 7 days, is used as a criterion for determining the discharge date. For a subset of infants, however, the persistence of cardiorespiratory events may delay discharge. In these infants, apnea longer than 20 seconds is rare; rather, they exhibit frequent bradycardia to less than 70 or 80 beats/min with short respiratory pauses. The reason why some infants exhibit marked bradycardia with short pauses is unclear. For a few of these infants, home cardiorespiratory monitoring until 43 to 44 weeks' postconceptional age may offer an alternative to a prolonged hospital stay.
Apnea and Sudden Infant Death Syndrome
The apparent lack of a relationship between persistent apnea of prematurity and sudden infant death syndrome (SIDS) has become clearer in recent years. Significant progress in reducing the rate of SIDS was made with the "Back to Sleep" program for term and preterm infants. This effort was based on the observation that decreasing the incidence of prone sleeping (in conjunction with avoidance of cigarette smoke exposure and overheating of an infant) reduced the rate of SIDS. The finding of an intervention that decreased SIDS rates helped remove some of the mystery surrounding these deaths that are by definition unexplained. Apnea and SIDS remain linked epidemiologically because they both occur in certain population groups (eg, preterm infants). Although early case reports seemed to indicate that children who had apnea were at risk of dying of SIDS, careful analysis of a large cohort of infants failed to find any relationship between apnea and later deaths. Currently, no clinical evidence reliably links a ventilatory control abnormality to SIDS. 
Long-term Effect of Apnea
Because idiopathic apnea is seen most often in high-risk preterm infants, separating the consequences of preterm birth from the effects of apnea of prematurity has proven difficult. Infants born prematurely often experience multiple problems during their time in the neonatal intensive care unit, and many of these conditions, particularly periventricular leukomalacia and intraventricular hemorrhage, may contribute to poor neurodevelopmental outcome. Additionally, studies that assess improvement in long-term outcome as a result of treating apnea of prematurity are few and confounded by these same issues.
Two recent reports of long-term follow-up of these at-risk infants have addressed this problem. In one cohort of preterm infants followed to early school age, apnea of prematurity was among the factors that predicted poor neurodevelopmental outcomes. The outcomes measured included cognitive function, neuropsychological abilities, academic achievement, and parent and teacher ratings of child behavior and school performance. In another series of very low-birthweight infants followed to 24 months of age, predischarge apnea correlated with lower mental and motor neurodevelopmental scores. Other series of case comparisons have reported no difference in the outcome of infants who have had apnea. It is possible that recurrent hypoxia is the detrimental feature of the breathing abnormalities exhibited by preterm infants. Finally, a possible relationship between apnea of prematurity and sleep-disordered breathing in childhood is being explored.
